PDS Biotechnology (NASDAQ:PDSB) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

PDS Biotechnology (NASDAQ:PDSB) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05), FiscalAI reports.

PDS Biotechnology Stock Performance

NASDAQ:PDSB traded down $0.00 during trading hours on Friday, reaching $0.23. The company had a trading volume of 1,742,584 shares, compared to its average volume of 2,164,556. The firm has a market cap of $12.90 million, a price-to-earnings ratio of -0.36 and a beta of 1.62. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 2.73. The firm’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.85. PDS Biotechnology has a 52 week low of $0.22 and a 52 week high of $1.55.

Analyst Upgrades and Downgrades

PDSB has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of PDSB. Virtu Financial LLC bought a new stake in shares of PDS Biotechnology during the 4th quarter valued at about $25,000. Marshall Wace LLP purchased a new position in shares of PDS Biotechnology in the second quarter worth approximately $91,000. Jane Street Group LLC purchased a new position in shares of PDS Biotechnology in the second quarter worth approximately $92,000. Susquehanna International Group LLP grew its position in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares during the period. Finally, Commonwealth Equity Services LLC grew its position in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares during the period. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.